MeSH D007003 - hypoglycemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals | Glucagon | Glucagon | 2020-12-28 | $116.523 M | Q2/23-Q1/24 | |
| Glucagon | Baqsimi | 2022-01-03 | 2019-07-24 | $42.544 M | Q3/23-Q1/24 | |
| APP Pharmaceuticals | Diazoxide | Diazoxide | 1987-08-26 | |||
| Eli Lilly | Glucagon | Baqsimi | 2019-12-16 | $699 M | Q2/22-Q3/23 | |
| Glucagon | Glucagon | 1982-01-01 | ||||
| Fresenius Kabi | Glucagon | Glucagon | 2015-05-08 | |||
| Merck Sharp & Dohme | Diazoxide | Hyperstat | 1982-01-01 | |||
| Novitium Pharma | Diazoxide | Diazoxide | 2020-07-08 | |||
| Novo Nordisk | Glucagon | Glucagen | 1998-06-22 | |||
| Tetris Pharma | Glucagon | Ogluo | 2021-02-11 | |||
| Teva | Diazoxide | Proglycem | 1982-01-01 | |||
| Xeris Pharmaceuticals | Glucagon | Gvoke | 2036-04-22 | 2019-09-10 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
69%27/39
Phase 2
35%12/34
Phase 3
81%13/16
Approved: 3Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use